So far in 2022, IPO activity has been dominated by small, volatile issuers. Of the year’s 51 pricings to date, 19 (37%) have soared 100% or more in their debuts, while one-in-ten have jumped at least 500%. But those with the largest first-day pops have...read more
Companies have broadly put listing plans on hold amid the worst IPO sell-off in over a decade, but small issuers are still on the move. So far, 21 of the year’s 34 IPOs (62%) have raised less than $50 million, the highest concentration in over a decade....read more
Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price swings thanks to interest from momentum...read more
2022 IPOs with the largest first-day pops are now some of the worst performers
So far in 2022, IPO activity has been dominated by small, volatile issuers. Of the year’s 51 pricings to date, 19 (37%) have soared 100% or more in their debuts, while one-in-ten have jumped at least 500%. But those with the largest first-day pops have...read more
Tiny takeover: Small issuers account for over 60% of 2022 IPO activity
Companies have broadly put listing plans on hold amid the worst IPO sell-off in over a decade, but small issuers are still on the move. So far, 21 of the year’s 34 IPOs (62%) have raised less than $50 million, the highest concentration in over a decade....read more
Renaissance Capital's April IPO Market Update
After the IPO market's slowest first quarter in six years, eight IPOs raised $725 million in April, a 75% y/y decline in deal count...read more
US IPO Weekly Recap: 4 IPOs price, led by norovirus biotech HilleVax
Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price swings thanks to interest from momentum...read more